<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        121-116-18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ROLITAC 5 mg Capsule
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TACROLIMUS
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2350.808
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Sandoz Private Limited" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Sandoz Private Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SANDOZ
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AD02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Rolitac </strong>&nbsp;belongs to a group of medicines called <strong>immunosuppressants</strong>.</p><p>Following your organ transplant (e.g. liver, kidney, heart), your body&rsquo;s immune system will try to reject the new organ.</p><p><strong>Rolitac </strong>&nbsp;is used to control your body&rsquo;s immune response enabling your body to accept the transplanted organ.</p><p><strong>Rolitac </strong>&nbsp;is often used in combination with other medicines that also suppress the immune system.</p><p>&nbsp;</p><p>You may also be given <strong>Rolitac </strong>&nbsp;for an ongoing rejection of your transplanted liver, kidney, heart or other organ or if any previous treatment you were taking was unable to control this immune response after your transplantation.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Rolitac :</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic (hypersensitive) to tacrolimus or any of the other ingredients of Rolitac</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic (hypersensitive) to any antibiotic belonging to the subgroup of macrolide antibiotics (e.g. erythromycin, clarithromycin, josamycin).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking <strong>Rolitac </strong>.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor If you have diarrhoea for more than one day, because it might be necessary to adapt the dose of <strong>Rolitac </strong>&nbsp;that you receive.</p><p>&sect;&nbsp; Tell your doctor If you have liver problems or have had a disease which may have affected your liver, because this may affect the dose of <strong>Rolitac </strong>&nbsp;that you receive.</p><p>&sect;&nbsp; Limit your exposure to sunlight and UV light by wearing appropriate protective clothing and using a sunscreen with a high protection factor. This is because of the potential risk of malignant skin changes with immunsuppressive therapy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take <strong>Rolitac </strong>&nbsp;every day as long as you need immunosuppression to prevent rejection of your transplanted organ. You should keep in regular contact with your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Whilst you are taking <strong>Rolitac </strong>&nbsp;your doctor may want to carry out a number of tests (including blood, urine, heart function, visual and neurological tests) from time to time. This is quite normal and will help your doctor to decide on the most appropriate dose of <strong>Rolitac </strong>&nbsp;for you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; please inform your doctor beforehand. If you need to have any vaccinationss. Your doctor will advice you on the best course of action</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please avoid taking any herbal remedies, e.g. St. John&rsquo;s wort (<em>Hypericum perforatum</em>) or any other herbal products as this may affect the effectiveness and the dose of <strong>Rolitac </strong>&nbsp;that you need to receive. If in doubt please consult your doctor prior to taking any herbal products or remedies.</p><p>&nbsp;</p><p><strong>Taking Other medicines </strong></p><p>Please tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription and herbal remedies.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Rolitac </strong>&nbsp;blood levels can be affected by other medicines you take, and blood levels of other medicines can be affected by taking <strong>Rolitac </strong>&nbsp;which may require interruption, an increase or a decrease in <strong>Rolitac </strong>&nbsp;dose.</p><p>&nbsp;</p><p><strong>Take care with the following medicines:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antifungal medicines and antibiotics, particularly so-called macrolide antibiotics) used to treat infections e.g. ketoconazole, fluconazole, itraconazole, voriconazole, clotrimazole, erythromycin, clarithromycin, josamycin and rifampicin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; HIV protease inhibitors e.g. ritonavir</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; HCV protease inhibitors (e.g. telaprevir, boceprevir), used to treat hepatitis C infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The anti-ulcer substance omeprazole or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hormone treatments with ethinylestradiol (e.g. the oral contraceptive pill) or danazol</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for high blood pressure or heart problems such as nifedipine, nicardipine, diltiazem and verapamil</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines known as &ldquo;statins&rdquo; used to treat elevated cholesterol and triglycerides</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the anti-epileptic medicines phenytoin or phenobarbital</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the corticosteroids prednisolone and methylprednisolone</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the anti-depressant nefazodone</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s Wort (hypericum perforatum)</p><p>Rolitac must not be taken with ciclosporin</p><p><strong>&nbsp;</strong></p><p>Your doctor also needs to know if you are taking potassium supplements or potassium-sparing diuretics (e.g. amiloride, triamterene or spironolactone), certain pain killers (so-called NSAIDs, e.g. ibuprofen), anticoagulants or oral medication for diabetic treatment, while you take <strong>Rolitac </strong>.The use of ibuprofen, amphotericin B, antivirals (e.g. acyclovir), may worsen kideny or nervous system problems when taken together with Rolitac.</p><p>&nbsp;</p><p><strong>Rolitac </strong><strong>&nbsp;with food and drink</strong></p><p>You should generally take <strong>Rolitac </strong>&nbsp;on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal. Grapefruit and grapefruit juice should be avoided while taking <strong>Rolitac </strong>.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;Rolitac </strong>&nbsp;is excreted into breast milk. Therefore you should not breast-feed whilst receiving <strong>Rolitac </strong>.</p><p>&nbsp;</p><p><strong>Driving and using machines:</strong></p><p>Do not drive or use any tools or machines if you feel dizzy or sleepy, or have problems seeing clearly after taking <strong>Rolitac </strong>. These effects are more frequently observed if <strong>Rolitac </strong>&nbsp;is taken in conjunction with alcohol use.</p><p>&nbsp;</p><p><strong>Important information about some of the ingredients of</strong><strong> </strong></p><p>This medicine contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Rolitac exactly as your doctor has told you. You should Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><u>The usual dose is as follows:</u></p><p>&nbsp;</p><p>Make sure that you receive the same tacrolimus medicine every time you collect your prescription, unless your transplant specialist has agreed to change to a different tacrolimus medicine.</p><p>This medicine should be taken twice a day. If the appearance of this medicine is not the same as usual, or if dosage instructions have changed, speak to your doctor or pharmacist as soon as possible to make sure that you have the right medicine.</p><p>&nbsp;</p><p>The starting dose to prevent the rejection of your transplanted organ will be determined by your doctor calculated according to your body weight. Initial doses just after transplantation will generally be in the range of</p><p>&nbsp;</p><p>0.075&ndash;0.30 mg per kg body weight per day</p><p>&nbsp;</p><p>depending on the transplanted organ.</p><p>&nbsp;</p><p>Your dose depends on your general condition and on which other immunosuppressive medication you are taking. Regular blood tests by your doctor will be required to define the correct dose and to adjust the dose from time to time. Your doctor will usually reduce your <strong>Rolitac </strong>&nbsp;dose once your condition has stabilised. Your doctor will tell you exactly how many capsules to take and how often.</p><p><strong>&nbsp;</strong></p><p><strong>Method and route of administration</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Rolitac </strong>&nbsp;is taken orally twice daily, usually in the morning and evening. You should generally take <strong>Rolitac </strong><strong>&nbsp;</strong>on an empty stomach or at least 1 hour before or 2 to 3 hours after the meal.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow your capsules whole with a glass of water.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Avoid grapefruit and grapefruit juice while taking <strong>Rolitac </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take the hard capsules immediately following removal from the blister.</p><p>&sect;&nbsp; Do not swallow the desiccant contained in the foil wrapper.</p><p>&nbsp;</p><p><strong>If you take more </strong><strong>Rolitac </strong><strong>&nbsp;than you should</strong></p><p>If you have accidentally taken too much <strong>Rolitac </strong>&nbsp;or if someone else accidentally takes your medicine, see your doctor or contact your nearest hospital emergency department immediately.</p><p>&nbsp;</p><p><strong>If you forget to take </strong><strong>Rolitac </strong></p><p>Do not take a double dose to make up for forgotten individual doses.</p><p>If you have forgotten to take your <strong>Rolitac </strong>&nbsp;capsules, wait until it is time for the next dose, and then continue as before.</p><p>&nbsp;</p><p><strong>If you stop taking </strong><strong>Rolitac </strong></p><p>Stopping your treatment with <strong>Rolitac </strong>&nbsp;may increase the risk of rejection of your transplanted organ. Do not stop your treatment unless your doctor tells you to do so.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Rolitac can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Rolitac </strong>&nbsp;reduces your body&rsquo;s own defence mechanism to stop you rejecting your transplanted organ. Consequently, your body will not be as good as usual at fighting infections. So if you are taking <strong>Rolitac </strong>&nbsp;you may therefore catch more infections than usual such as infections of the skin, mouth, stomach and intestines, lungs and urinary tract.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe effects have been reported, including allergic and anaphylactic reactions. Benign and malignant tumours have been reported following Tacrolimus treatment as a result of immunosuppression.</p><p>&nbsp;</p><p><strong>Serious side effects</strong></p><p>&nbsp;</p><p>If you notice one of the following serious side effects, talk to your doctor or <strong>go to a hospital immediately:</strong></p><p>&nbsp;</p><p>&sect;&nbsp; In case of any evidence of infection (e.g. fever, sore throat), unexpected bruising and/or bleeding</p><p>&sect;&nbsp; Hypersensitivity reactions (anaphylaxis, angioedema): If you develop a swelling of the eyelids, face, lips, mouth or tongue, start to itch or have difficulty breathing or swallowing, or extreme dizziness.</p><p>&nbsp;</p><p>Following serious side-effects are <strong>common</strong> (may affect up to 1 in 10 people):</p><p>&sect;&nbsp;&nbsp; Unusual bruising or bleeding, including vomiting blood or passing blood in your stools</p><p>&sect;&nbsp;&nbsp; Fits (convulsions)</p><p>&sect;&nbsp;&nbsp; Yellowing of the skin and eyes, unusual tiredness or fever, dark coloured urine (signs of inflamed liver).</p><p>&nbsp;</p><p>Following serious side-effects are <strong>uncommon</strong> (may affect up to 1 in 100 people):</p><p>&sect;&nbsp; Coma, stroke, paralysis</p><p>&sect;&nbsp; Irregular heartbeat or stop of heartbeat</p><p>&sect;&nbsp; Shock</p><p>&nbsp;</p><p>Following serious side-effects are <strong>rare</strong> (may affect up to 1 in 1,000 people):</p><p>&sect;&nbsp; Feeling of tightness in your chest</p><p>&sect;&nbsp; Acute breathlessness</p><p>&sect;&nbsp; Serious illness with blistering of skin, mouth, eyes and genitals</p><p>&nbsp;</p><p>Following serious side-effects are <strong>very rare</strong> (may affect up to 1 in 10,000 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Painful urination with blood in the urine</p><p>&sect;&nbsp; Severe illness with ulceration of the mouth, lips and skin</p><p>&nbsp;</p><p>These are all serious side effects. You may need urgent medical attention.</p><p>&nbsp;</p><p>Other possible side-effects</p><p>&nbsp;</p><p><u>Following side-effects are very common (may affect more than 1 in 10 people):</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trembling, headache, difficulty in sleeping</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea, nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood sugar, diabetes mellitus, increased potassium in the blood</p><p>&nbsp;</p><p><u>Following side-effects are common (may affect up to 1 in 10 people):</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction in blood cell counts (platelets, red or white blood cells), increase in white blood cell counts, changes in red blood cell counts, reduced blood flow in the heart vessels, faster heartbeat, bleeding, partial or complete blocking of blood vessels, reduced blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disturbances in consciousness, tingling and numbness (sometimes painful) in the hands and feet, dizziness, impaired writing ability, nervous system disorders, anxiety symptoms, confusion and disorientation, depression, mood changes, nightmare, hallucination, mental disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision, increased sensitivity to light, eye disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ringing sound in your ears</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness in breath, changes in the lung tissue, collection of liquid around the lung, inflammation of the pharynx, cough, flu-like symptoms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammations or ulcers causing abdominal pain or diarrhoea, inflammations or ulcers in the mouth, collection of fluid in the belly, vomiting, abdominal pains, indigestion, constipation, flatulence, bloating, loose stools, stomach problems, changes in liver enzymes and function</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching, rash, hair loss, acne, increased sweating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; insufficient function of the kidneys, reduced production of urine, impaired or painful urination</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in joints, limbs or back, muscle cramps</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced magnesium, phosphate, potassium, calcium or sodium in the blood, fluid overload, increased uric acid or lipids in the blood, decreased appetite, increased acidity of the blood, other changes in the blood salts</p><p>general weakness, collection of fluid in your body, pain and discomfort, increase of the enzyme alkaline phosphatase in your blood, weight gain, feeling of temperature disturbed, as can happen in patients taking this type of medicine, a very small number of tacrolimus patients have developed cancer of the lymphoid tissues and skin.</p><p>insufficient function of your transplanted organ</p><p>&nbsp;</p><p><u>Following side-effects are uncommon (may affect up to 1 in 100 people): </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in blood clotting, reduction in all blood cell counts, reduced performance of your heart, disorder of the heart muscle, enlargement of the heart muscle, stronger heartbeat, abnormal ECG, heart rate and pulse abnormal, blood clot in a vein of a limb</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding in the brain, brain disorder, speech and language abnormalities, memory problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; opacity of the lens</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impaired hearing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>difficulties in breathing, respiratory tract disorders, asthma</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>obstruction of the gut, peritonitis, severe upper stomach pain, increased blood level of the enzyme amylase, reflux of stomach content in your throat, delayed emptying of the stomach</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>inability to urinate, painful menstruation and abnormal menstrual bleeding</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>dermatitis, burning sensation in the sunlight</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>joint disorders</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>dehydration, reduced protein or sugar in the blood, increased phosphate in the blood</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>failure of some organs, influenza like illness, increased sensitivity to heat and cold, feeling of pressure on your chest, jittery or abnormal feeling, increase of the enzyme lactate dehydrogenase in your blood, weight loss</u></p><p><u>&nbsp;</u></p><p><u>Following side-effects are are (may affect up to 1 in 1,000 people): </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; small bleedings in your skin due to blood clots, collection of fluid around the heart</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased muscle stiffness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blindness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; deafness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute breathlessness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; partial obstruction of the gut, cyst formation in your pancreas, problems with blood flow in the liver</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased hairiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thirst, fall, decreased mobility, ulcer</p><p>&nbsp;</p><p><u>Following side-effects are very rare (may affect up to 1 in 10,000 people): </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; echocardiogram abnormal</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscular weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver failure, narrowing of the bile vessel</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of fat tissue</p><p>&nbsp;</p><p>Cases of pure red cell aplasia (a very severe reduction in red blood cell counts), agranulocytosis (a severely lowered number of white blood cells) and haemolytic anaemia (decreased number of red blood cells due to abnormal breakdown) have been reported.</p><p>If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. However, do not stop taking your medicine unless you have discussed this with your doctor first</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Use all the capsules within 12 months of opening the aluminium wrapping surrounding the blister. Do not store above 25&deg;C after opening the aluminium wrapping.</p><p>&nbsp;</p><p>Take the capsule immediately after removing from the blister.</p><p>&nbsp;</p><p>Do not store above 30&deg;C. Store in the original package in order to protect from moisture.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines no longer reguired. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is tacrolimus. Each capsule contains 0.5 mg, 1 mg, or 5 mg of tacrolimus (as monohydrate).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Capsule contents:</em> lactose monohydrate, hypromellose, croscarmellose sodium and magnesium stearate</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Hard gelatin capsule: </em></p><p>Rolitac, 0.5 mg: gelatin, titanium dioxide (E 171), sodium laurilsulfate, sorbitan laureate and yellow iron oxide (E 172).</p><p>Rolitac, 1 mg: gelatin, titanium dioxide (E 171), sodium laurilsulfate, sorbitan laureate, yellow iron oxide (E 172), red iron oxide (E 172) and black iron oxide (E 172).</p><p>Rolitac, 5 mg: gelatin, titanium dioxide (E 171), sodium laurilsulfate, sorbitan laureate and red iron oxide (E 172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Rolitac, 0.5 mg are hard capsules with white coloured opaque body and ivory coloured cap containing white to off- white powder (length: 14.5 mm).
	
	
	Rolitac, 1 mg are hard capsules with white coloured opaque body and light brown coloured cap containing white to off- white powder (length: 14.5 mm).
	
	
	Rolitac, 5 mg are hard capsules with white coloured opaque body and orange coloured cap containing white to off- white powder (length: 15.8 mm).
	
	Rolitac  are packed in PVC/ PE/ PVdC/ Aluminium blisters in Aluminium bag, including a dessicant protecting the capsules from moisture. The dessicant should not be swallowed.
	Pack size are country specific

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>Sandoz GmbH</p><p>Biochemiestrasse 10 Kundl, Austria</p><p><strong>Manufacturer</strong></p><p><br />Sandoz Private Limited</p><p>Navi Mumbai, India</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                June 2010
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي روليتاك إلى فئة من الأدوية تسمى کوابت المناعة.</p><p dir="RTL">بعد زراعة أحد الأعضاء (كالكبد أو الكلية أو القلب) سيحاول الجهاز المناعي في جسمك أن يرفض العضو الجديد. ولذلك فإن روليتاك يستعمل للتحكم بالاستجابة المناعية في جسمك مما يؤدي بالتالي إلى أن جسمك سيقبل العضو الجديد المزروع.</p><p dir="RTL">وكثيراً ما يستعمل روليتاك بالاتحاد مع أدوية أخرى كابتة للجهاز المناعي.</p><p dir="RTL">كما وقد يوصي لك الطبيب بأخذ روليتاك لأن جسمك يرفض باستمرار إحدى الزراعات كالكبد أو الكلية أو القلب أو غيرها من الأعضاء، أو لأن أحد العلاجات السابقة الذي كنت تأخذه لم يتمكن من التحكم بالاستجابة المناعية في جسمك بعد الزراعة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تأخذ روليتاك في الحالات التالية</strong><strong>:</strong></p><p dir="RTL">&bull; إذا كنت تعاني من الأرجية (فرط الحساسية) لمادة تاکرولیموس أو أي من العناصر والمكونات الأخرى التي يحتوي عليها روليتاك .</p><p dir="RTL">&bull; إذا كنت تعاني من الأرجية (فرط الحساسية) لأي مضاد حيوي ينتمي إلى الفئة الفرعية للمضادات الحيوية الماكروليدية (على غرار إريثرومايسين أو كلاريثرومايسين أو جوسامایسین).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يجب عليك توخي الحذر الخاص مع روليتاك في الحالات التالية</strong><strong>:</strong></p><p dir="RTL">&bull; أخبر طبيبك إذا أصبحت تعاني من الإسهال لأكثر من يوم، نظراً لأن الأمر قد يتطلب تعديل جرعة روليتاك التي تحصل عليها.</p><p dir="RTL">&bull; أخبر طبيبك إذا كنت حالياً تعاني من مشاكل في الكبد أو إذا سبق وأن كنت مصاباً بمرض قد أثر على كبدك، حيث أن ذلك قد يؤثر على جرعة روليتاك التي تتناولها.</p><p dir="RTL">&bull; قلل من نسبة تعرضك لأشعة الشمس والأشعة فوق البنفسجية من خلال ارتداء ملابس واقية مناسبة واستعمال کریم واق من الشمس يتميز بعامل وقاية عالي، وذلك بسبب مخاطر حدوث تغيرات جلدية خبيثة عند العلاج الكابت للمناعة.</p><p dir="RTL">&bull; تناول روليتاك كل يوم طيلة فترة احتياجك للعلاج الكابت للمناعة وذلك لمنع جسمك من رفض العضو المزروع. كما وينبغي عليك البقاء على اتصال مستمر مع طبيبك.</p><p dir="RTL">&bull; أثناء أخذك روليتاك قد يقرر طبيبك إجراء عدد من الفحوصات (بما فيها فحوصات الدم والبول والوظيفة القلبية وفحوصات البصر والأعصاب) بين الحين والآخر. إن ذلك أمر عادي يساعد طبيبك على تحديد الجرعة الأكثر تناسباً وحالتك من روليتاك.</p><p dir="RTL">&bull; يرجى إعلام طبيبك مسبقاً إذا احتجت لأية مطاعيم، حيث سينصحك حول ما يجب فعله.</p><p dir="RTL">&bull; يرجى تجنب تناول أية علاجات نباتية مثل عشبة القديسين (عصبة القلب) أو أية منتجات عشبية أخرى نظراً لأن ذلك قد يؤثر على فعالية روليتاك والجرعة التي تحتاجها. إذا لم تكن متأكداً استشر الطبيب قبل تناول أية منتجات أو علاجات عشبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخذ أدوية أخرى</strong><strong>:</strong></p><p dir="RTL">يرجى إعلام الطبيب أو الصيدلاني إذا كنت تأخذ أدوية أخرى أو إذا أخذتها مؤخراً حتى ولو لم تكن هذه الأدوية تستدعي وصفة طبية والعلاجات العشبية .</p><p dir="RTL">قد يتأثر تركيز روليتاك في الدم عند أخذ أدوية أخرى، أو أن تركيزات الأدوية الأخرى في الدم قد تتأثر عند تناول روليتاك مما يتطلب بدوره زيادة أو تخفيض جرعة روليتاك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يجب عليك توخي الحذر مع الأدوية التالية</strong><strong>:</strong></p><p dir="RTL">&bull; الأدوية المضادة للفطريات والمضادات الحيوية - خاصة المضادات الحيوية الماكروليدية على غرار کیتوکونازول، فلوكونازول، إيتراكونازول، فوریکونازول، كلوتريمازول، إريثرومايسين، كلاريثرومايسين، جوسامايسين، ريفامبيسين</p><p dir="RTL">&bull; مثبطات إنزيم بروتياز فيروس نقص المناعة البشرية على غرار ریتونافير</p><p dir="RTL">&bull; أوميبرازول وهي مادة مضادة للقرحات</p><p dir="RTL">&bull; العلاجات الهرمونية التي تحتوي على إيثينيل إيستراديول (مثل حبوب منع الحمل الفموية) أو دانازول.</p><p dir="RTL">&bull; الأدوية المستعملة في معالجة ارتفاع ضغط الدم والمشاكل القلبية على غرار نيفيديبين أو نیکاردیبين أو ديلتيازيم أو فيراباميل</p><p dir="RTL">&bull; الأدوية المسماه بـ &quot;الستاتينات&quot; والمستعملة في معالجة ارتفاع الكولسترول وثلاثيات الغليسريد</p><p dir="RTL">&bull; مضادات الصرع فينيتوئين أو فينوباربیتال</p><p dir="RTL">&bull; الكورتيكوستيروئيدات بريدنيزولون وميثيل البريدنيزولون</p><p dir="RTL">&bull; نيفازودون وهو مضاد للاكتئاب</p><p dir="RTL">&bull; عشبة القديسين (عصبة القلب).</p><p dir="RTL">لا يجوز تناول روليتاك مع سيكلوسبورين.</p><p dir="RTL">كما ويحتاج طبيبك لمعرفة فيما إذا كنت حالياً تأخذ أحد مكملات البوتاسيوم أو مدرات البول الموفرة للبوتاسيوم (على غرار أميلوراید أو تریامترين أو سبيرونولاکتون): أو بعض أنواع مسكنات الألم المعينة (والمسماه بالأدوية اللاستيروئيدية المضادة للإلتهاب مثل إيبوبروفين)، أو مضادات التخثر، أو الأدوية التي تؤخذ بالفم لمعالجة السكري أثناء أخذك روليتاك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن استعمال إيبوبروفين، أو أمفوتيريسين ب، أو مضادات الفيروسات (على غرار أسيكلوفير) قد يساهم في تفاقم المشاكل الكلوية أو مشاكل الجهاز العصبي عند أخذها في نفس الوقت مع روليتاك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخذ روليتاك مع الغذاء والشراب</strong></p><p dir="RTL">بشكل عام ينبغي عليك أخذ روليتاك إما على معدة فارغة أو قبل ساعة على الأقل من تناول وجبة الطعام أو بعد مرور ٢-٣ ساعات على الأقل من تناول الوجبة. تجنب تناول الجريب فروت أو عصير الجريب فروت أثناء أخذ روليتاك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع</strong></p><p dir="RTL">&bull; إذا خططت للحمل أو إذا اعتقدت بأنك حامل استشيري الطبيب أو الصيدلاني قبل أخذ أية أدوية.</p><p dir="RTL">&bull; يدخل روليتاك في حليب الأم ولذلك ينبغي عليك عدم الإرضاع أثناء أخذك المستحضر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة وتشغيل الماكينات والأجهزة</strong><strong>:</strong></p><p dir="RTL">لا تقم بقيادة السيارات أو تشغيل الماكينات والأجهزة إذا شعرت بالدوخة أو النعاس أو عدم وضوح الرؤية بعد أخذك مستحضر روليتاك. وقد روقب حدوث مثل هذه التأثيرات على نحو أكثر تكراراً عند أخذ روليتاك في نفس وقت تناول الكحول.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض العناصر التي يحتوي عليها روليتاك</strong><strong>:</strong></p><p>يحتوي هذا الدواء على اللاكتوز. فإذا أخبرك طبيبك بأنك تعاني من عدم تحمل لبعض أنواع السكر يجب عليك مراجعته قبل أخذ هذا المنتج الطبي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب عليك دائماً تناول روليتاك وفقاً لإرشادات الطبيب بالضبط. وينبغي عليك استشارة الطبيب أو الصيدلاني إذا لم تكن متأكداً. وتكون الجرعة المعتادة كما يلي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">تأكد من حصولك على نفس دواء تاکرولیموس في كل مرة تأخذ بها الوصفة، إلا إذا وافق الطبيب المتخصص بالزراعة على استبدال هذا الدواء بدواء آخر من تاکرولیموس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يؤخذ الدواء مرتين في اليوم. إذا تغير مظهر وشكل الدواء وكان مختلفاً عن المعتاد، أو إذا تغيرت إرشادات الجرعة تكلم مع الطبيب أو الصيدلاني بأسرع وقت ممكن للتأكد من أنك حاصل على الدواء الصحيح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن جرعة البداية اللازمة لمنع جسمك من رفض العضو المزروع سيحددها الطبيب حيث يحسبها بناءً على وزن جسمك. وعموماً فإن جرعات البداية التي تُعطي مباشرة بعد الزراعة تكون في النطاق التالي:</p><p dir="RTL">٠،٠٧٥-٠،٣٠ ملغم لكل كيلوغرام من وزن الجسم في اليوم وذلك حسب العضو المزروع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تعتمد جرعتك على حالتك العامة وعلى نوع کوابت المناعة الأخرى التي تأخذها. وسيقوم طبيبك بإجراء فحوصات منتظمة للدم لتحديد الجرعة السليمة ثم تعديل الجرعة بين الحين والآخر. كما وسيقوم طبيبك عموماً بتخفيض جرعة روليتاك حالما تستقر حالتك. وسيخبرك الطبيب بالضبط عدد الكبسولات التي يجب عليك أخذها وكم مرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة الاستعمال</strong></p><p dir="RTL">&bull; يؤخذ روليتاك عن طريق الفم مرتين في اليوم، عادة في الصباح والمساء. وعموماً ينبغي عليك تناول روليتاك إما على معدة فارغة أو قبل ساعة على الأقل من تناول وجبة الطعام أو بعد ٢-٣ ساعات على الأقل من تناول الوجبة.</p><p dir="RTL">&bull; تُبلع الكبسولات كاملة مع كوب من الماء.</p><p dir="RTL">&bull; تجنب تناول الجريب فروت أو عصير الجريب فروت أثناء أخذك روليتاك.</p><p dir="RTL">&bull; تناول الكبسولات الصلبة مباشرة بعد إخراجها من الشريط.</p><p dir="RTL">&bull; لا تبلع المادة المجففة الموجودة داخل مغلف الألومنيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أخذت كمية أكبر مما ينبغي من روليتاك</strong><strong>:</strong></p><p dir="RTL">إذا أخذت بالخطأ كمية أكبر مما ينبغي من روليتاك، أو إذا أخذ غيرك بالصدفة الدواء المخصص لك أنت، عندها راجع طبيبك فوراً أو قسم الطوارىء في أقرب مستشفى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا نسيت أخذ روليتاك</strong><strong>:</strong></p><p dir="RTL">لا تأخذ ضعف الجرعة لتعويض الجرعة التي فاتتك. فإذا اقترب وقت تناول الجرعة القادمة انتظر واستمر حسب الجدول المعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن أخذ روليتاك</strong><strong>:</strong></p><p dir="RTL">إن التوقف عن أخذ روليتاك قد يزيد من مخاطر رفض جسمك للعضو المزروع. ولذلك لا تتوقف عن المعالجة ما لم يأمرك الطبيب بذلك.</p><p>للمزيد من الأسئلة والاستفسارات حول استعمال هذا المنتج يرجى استشارة الطبيب أو الصيدلاني</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية قد يسبب روليتاك أعراضاً جانبية، رغم أن ليس الجميع سيصاب بها.</p><p dir="RTL">يعمل روليتاك على تخفيض آلية الدفاع في جسمك وذلك بهدف منع الجسم من رفض العضو المزروع. ونتيجة لذلك فإن جسمك لن يتمكن من مكافحة العدوى بالطريقة التي اعتادها. وبالتالي فإنه عند أخذك روليتاك قد تصاب على نحو أكثر بالعدوى عن المعتاد مثل عدوى الجلد أو الفم أو المعدة أو الأمعاء أو الرئتين أو الجهاز البولي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لقد وردت تقارير عن حدوث تأثيرات شديدة بما فيها التفاعلات الأرجية والتفاعلات التأقية.</p><p dir="RTL">كما وقد وردت تقارير عن نشوء الأورام الحميدة والخبيثة بعد العلاج بتاکرولیموس وذلك نتيجة كبت المناعة في الجسم .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الخطيرة</strong></p><p dir="RTL">إذا لاحظت أحد الأعراض الجانبية الخطيرة التالية تكلم مع طبيبك أو <strong>راجع المستشفى فوراً</strong><strong> </strong><strong>:</strong></p><p dir="RTL">&bull; في حال وجود أي دليل على وجود عدوى (كالحمى أو إلتهاب الحلق)، أو تكدمات غير متوقعة و/أو نزيف</p><p dir="RTL">&bull; تفاعلات فرط الحساسية (تأق، وذمة وعائية): إذا أصابك انتفاخ في الجفون أو الوجه أو الشفتين أو الفم أو اللسان، أو إذا أصابتك حكة أو صعوبة في التنفس أو البلع أو إذا أصابتك دوخة شديدة</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأعراض الجانبية الخطيرة التالية <strong>شائعة</strong></p><p dir="RTL">(تصيب ١ إلى ١٠ أشخاص من بين ١٠٠):</p><p dir="RTL">&bull; &nbsp;کدمات غير طبيعية أو نزيف بما فيه تقيؤ الدم أو وجود دم في البراز</p><p dir="RTL">&bull; &nbsp;نوبات (تشنجات)</p><p dir="RTL">&bull; &nbsp;اصفرار الجلد والعينين، تعب غير طبيعي أو حمی، بول ملون غامق (دلائل على إلتهاب الكبد)</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأعراض الجانبية الخطيرة التالية <strong>غير شائعة</strong></p><p dir="RTL">(تصيب ١ إلى ١٠ أشخاص من بين ١٠٠٠):</p><p dir="RTL">&bull; غيبوبة، سكتة، شلل</p><p dir="RTL">&bull; نبض قلبي غير منتظم أو توقف القلب</p><p dir="RTL">&bull; صدمة</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأعراض الجانبية الخطيرة التالية <strong>نادرة</strong></p><p dir="RTL">(تصيب ١ إلى ١٠ مستعملين من بین ١٠٠٠٠):</p><p dir="RTL">&bull; شعور بضيق الصدر</p><p dir="RTL">&bull; ضيق نفس حاد</p><p dir="RTL">&bull; مرض خطير ترافقه النفطات والتقرحات في الجلد والفم والعينين والأعضاء التناسلية</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأعراض الجانبية الخطيرة التالية <strong>نادرة جداً</strong></p><p dir="RTL">(تصيب أقل من ١ من بین ١٠٠٠٠ شخص):</p><p dir="RTL">&bull; ألم عند التبول يرافقه دم في البول</p><p dir="RTL">&bull; مرض شديد يرافقه تقرح الفم والشفتين والجلد</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذه جميعها أعراض جانبية خطيرة، وقد تحتاج لرعاية طبية طارئة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية أخرى ممكن حدوثها</strong></p><p dir="RTL">الأعراض الجانبية التالية <strong>شائعة جداً</strong></p><p dir="RTL">(تصيب أكثر من ١ من بين ١٠ أشخاص):</p><p dir="RTL">&bull; ارتفاع ضغط الدم</p><p dir="RTL">&bull; رجفان، صداع، صعوبة في النوم</p><p dir="RTL">&bull; إسهال، غثيان</p><p dir="RTL">&bull; مشاكل كلوية</p><p dir="RTL">&bull; ارتفاع سكر الدم، مرض السكري، ارتفاع مستويات البوتاسيوم في الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأعراض الجانبية التالية <strong>شائعة</strong></p><p dir="RTL">(تصيب ١ إلى ١٠ أشخاص من بین ١٠٠):</p><p dir="RTL">&bull; انخفاض في عدد خلايا الدم (الصفيحات، خلايا الدم الحمراء أو البيضاء)، زيادة في عدد خلايا الدم البيضاء، تغيرات في عدد خلايا الدم الحمراء، انخفاض تدفق الدم في الأوعية القلبية، تسرع النبض القلبي، نزيف، انسداد جزئي أو كامل في أوعية الدم، انخفاض ضغط الدم.</p><p dir="RTL">&bull; اضطرابات في الوعي، وخز وخدر (یکون مؤلماً أحياناً) في اليدين والقدمين، دوخة ضعف القدرة على الكتابة، اضطرابات في الجهاز العصبي، أعراض القلق، ارتباك وتوهان، إكتئاب، تغيرات في المزاج، كوابيس، هلوسة، اضطرابات عقلية</p><p dir="RTL">&bull; عدم وضوح الرؤية، زيادة الحساسية للضوء، اضطرابات في العينين</p><p dir="RTL">&bull; صوت رنين في الأذنين</p><p dir="RTL">&bull; ضيق النفس، تغيرات في النسيج الرئوي، تجمع السوائل حول الرئة، إلتهاب الحلق،سعال، أعراض شبيهة بالإنفلونزا</p><p dir="RTL">&bull; إلتهابات أو قرحات تسبب الألم في البطن أو إسهال، إلتهابات أو قرحات في الفم، تجمع السوائل في البطن، تقيؤ، آلام بطنية، عسر الهضم، إمساك، ریح، انتفاخ البطن، براز لین، مشاكل في المعدة، تغيرات في الإنزيمات والوظيفة الكبدية</p><p dir="RTL">&bull; حكة، طفح، تساقط الشعر، حب الشباب، زيادة في التعرق</p><p dir="RTL">&bull; عدم كفاية وظيفة الكليتين، انخفاض في إنتاج البول، ضعف التبول أو ألم عند التبول</p><p dir="RTL">&bull; ألم في المفاصل أو الأطراف أو الظهر، تشنجات عضلية</p><p dir="RTL">&bull; انخفاض مستويات المغنيسيوم أو الفوسفات أو البوتاسيوم أو الكالسيوم أو الصوديوم في الدم، زيادة في السوائل، زيادة في حمض اليوريك أو الدهون في الدم، انخفاض الشهية، زيادة حموضة الدم، تغيرات أخرى في أملاح الدم</p><p dir="RTL">&bull; ضعف عام، تجمع السوائل في الجسم، ألم وتضايق، زيادة في إنزيم الفسفاتاز القلوي&nbsp; في الدم، زيادة في الوزن، شعور باضطراب درجة حرارة الجسم، وكما هو الأمر في المرضى الذين يأخذون هذا النوع من الدواء فإن عدداً قليلاً جداً من المرضى الخاضعين لعلاج بتاکرولیموس قد نشأ عندهم سرطان في الأنسجة اللمفاوية والجلد</p><p dir="RTL">&bull; عدم كفاية وظيفة العضو المزروع في جسمك</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأعراض الجانبية التالية <strong>غير شائعة</strong></p><p dir="RTL">(تصيب ١ إلى ١٠ أشخاص من بين ١٠٠٠):</p><p dir="RTL">&bull; تغيرات في التجلط الدموي، انخفاض في عدد جميع خلايا الدم، انخفاض أداء القلب، اضطراب عضلة القلب، تضخم عضلة القلب، ازدیاد قوة ضربات القلب، نتائج غير طبيعية عند تخطيط القلب، معدل ضربات القلب والنبض غير طبيعي، وجود جلطة دموية في أحد أوردة الأطراف</p><p dir="RTL">&bull; نزيف في الدماغ، اضطراب الدماغ، شذوذ في النطق واللغة، مشاكل في الذاكرة</p><p dir="RTL">&bull; عتامة العدسة</p><p dir="RTL">&bull; ضعف السمع</p><p dir="RTL">&bull; صعوبة في التنفس، اضطرابات في الجهاز التنفسي، ربو</p><p dir="RTL">&bull; انسداد الأمعاء، إلتهاب الصفاق، ألم شديد في المنطقة العلوية من المعدة، ارتفاع مستوى إنزيم الأميلاز في الدم، جزر &quot;ارتداد&quot; محتوى المعدة في الحلق، تأخر إفراغ المعدة</p><p dir="RTL">&bull; عدم القدرة على التبول، وجع عند الحيض ونزيف حيضي غير طبيعي</p><p dir="RTL">&bull; إلتهاب الجلد، إحساس بالحرق في ضوء الشمس</p><p dir="RTL">&bull; اضطرابات في المفاصل</p><p dir="RTL">&bull; جفاف، انخفاض مستوى البروتين أو السكر في الدم، ارتفاع مستوى الفوسفات في الدم</p><p dir="RTL">&bull; فشل بعض الأعضاء، مرض شبيه بالإنفلونزا، زيادة الحساسية للحرارة والبرودة، شعور بالضغط على الصدر، إحساس بالهياج العصبي &quot;النرفزة&quot; أو إحساس غير طبيعي، زيادة إنزيم نازعة هيدروجين اللاكتات في الدم، فقدان الوزن .</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأعراض الجانبية التالية <strong>نادرة</strong></p><p dir="RTL">(تصيب ١ إلى ١٠ مستعملين من بین ١٠٠٠٠)</p><p dir="RTL">&bull; نزوفات صغيرة في الجلد نتيجة الجلطات الدموية، تجمع السوائل حول القلب</p><p dir="RTL">&bull; زيادة في تيبس العضلات</p><p dir="RTL">&bull; عمى</p><p dir="RTL">&bull; صمم</p><p dir="RTL">&bull; ضيق النفس الحاد</p><p dir="RTL">&bull; انسداد جزئي في الأمعاء، تشكل الكيسات في البنكرياس، مشاكل بتدفق الدم في الكبد</p><p dir="RTL">&bull; کثرة الشعر</p><p dir="RTL">&bull; عطش، سقوط، ضعف القدرة على التحرك، قرحة</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأعراض الجانبية التالية <strong>نادرة جداً</strong></p><p dir="RTL">(تصيب أقل من ١ من بین ١٠٠٠٠ شخص):</p><p dir="RTL">&bull; مخطط صدى القلب غير طبيعي</p><p dir="RTL">&bull; ضعف عضلي</p><p dir="RTL">&bull; فشل كبدي، تضيق وعاء الصفراء</p><p dir="RTL">&bull; زيادة في النسيج الدهني</p><p dir="RTL">&nbsp;</p><p>إذا أصبح أي من الأعراض الجانبية خطيراً أو إذا لاحظت أية أعراض جانبية غير مذكورة في هذه النشرة، عندها يرجى إعلام الطبيب أو الصيدلاني. ولكن لا تتوقف عن أخذ الدواء ما لم تستشر طبيبك سلفاً.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيداً عن متناول أيدي الأطفال وأنظارهم.</p><p dir="RTL">لا تستعمل روليتاك بعد تاريخ انتهاء الصلاحية المبين على اللصاقة بعد عبارة &quot;EXP&quot; .</p><p dir="RTL">يشير تاريخ الانتهاء إلى آخر يوم من ذلك الشهر.</p><p dir="RTL">استعمل جميع الكبسولات في غضون ١٢ شهر من فتح مغلف الألومنيوم الذي يحيط بالشريط. يحفظ بدرجة حرارة لا تزيد عن ٢٥ &deg;م بعد فتح مغلف الألومنيوم.</p><p dir="RTL">تناول الكبسولة مباشرة بعد إخراجها من الشريط.</p><p dir="RTL">يحفظ في العبوة الأصلية لحمايته من الرطوبة. يحفظ بدرجة حرارة لا تزيد عن ٣٠ &deg; م.</p><p dir="RTL">ينبغي عدم التخلص من الأدوية عن طريق إلقائها في مياه الصّرف أو النفايات المنزلية.</p><p dir="RTL">يرجي الاستفسار لدى الصيدلاني عن كيفية إمكانية طرح الأدوية التي لم تعد بحاجة إليها. ستساعدك هذه الإجراءات على حماية البيئة والحفاظ عليها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- &nbsp;إن المادة الفعالة هي تاکرولیموس. كل كبسولة تحتوي على ٠،٥ ملغم، أو ١ ملغم، أو ٥ ملغم تاکرولیموس (على شكل مونوهیدرات).</p><p dir="RTL">- العناصر الأخرى هي:</p><p dir="RTL">&bull; <em>محتويات الكبسولة:</em> لاکتوز مونوهیدرات، هیبروميلوز، کروسکارمیلوز صوديوم، ستيارات المغنيسيوم.</p><p dir="RTL"><em>&bull;</em><em> </em><em>كبسولة جيلاتين صلبة</em><em>.</em></p><p dir="RTL"><em>روليتاك ٠،٥ ملغم:</em> جيلاتين، ثاني أكسيد التيتانيوم (إي ١٧١)، صوديوم لوریل سلفات، لوريات السوربيتان، أكسيد الحديد الأصفر (إي ١٧٢).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>روليتاك ١ ملغم:</em> جيلاتين، ثاني أكسيد التيتانيوم (إي ١٧١)، صوديوم لوریل سلفات، لوريات السوربيتان ، أكسيد الحديد الأصفر (إي ١٧٢)، أكسيد الحديد الأحمر (إي ١٧٢)، أكسيد الحديد الأسود (إي ١٧٢).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>روليتاك 5 ملغم:</em> جيلاتين، ثاني أكسيد التيتانيوم (إي ١٧١)، صوديوم لوریل سلفات، لوريات السوربيتان، أكسيد الحديد الأحمر (إي ١٧٢).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><em>روليتاك ٠،٥ ملغم</em> هي كبسولات صلبة ذات جسم غير شفاف أبيض اللون وغطاء عاجي اللون، وهي تحتوي على مسحوق أبيض ضارب إلى الصفرة.</p><p dir="RTL"><em>روليتاك ١ ملغم</em> هي كبسولات صلبة ذات جسم غير شفاف أبيض اللون وغطاء بني فاتح، وهي تحتوي على مسحوق أبيض ضارب إلى الصفرة.</p><p dir="RTL"><em>روليتاك ٥ ملغم</em> هي كبسولات صلبة ذات جسم غير شفاف أبيض اللون وغطاء برتقالي ، وهي تحتوي على مسحوق أبيض ضارب إلى الصفرة.</p><p dir="RTL">روليتاك معبأ في أشرطة مصنوعة من مادة ألومنيوم /PVC/PE/PVdC داخل كيس من الألومنيوم به مادة مجففة تحمي الكبسولات من الرطوبة. لا يجوز بلع المادة المجففة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن حجم العبوات يختلف من بلد لآخر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المالكة لحق التسويق</strong></p><p dir="RTL">ساندوز المحدودة، بيوكيمي شتراسه ١٠، ٦٢٥٠ کوندل / النمسا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p>ساندوز برايفات ليميتد، نافي مومباي، الهند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            حزيران ٢٠١٠
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rolitac , 0.5 mg, hard capsules
Rolitac , 1 mg, hard capsules
Rolitac , 5 mg, hard capsules

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rolitac , 0.5 mg, hard capsules
Each capsule contains 0.5 mg tacrolimus (as tacrolimus monohydrate).

Rolitac , 1 mg, hard capsules
Each capsule contains 1 mg tacrolimus (as tacrolimus monohydrate).

Rolitac , 5 mg, hard capsules
Each capsule contains 5 mg tacrolimus (as tacrolimus monohydrate).

Excipient(s):
Rolitac , 0.5 mg, hard capsules Each capsule contains 48.5 mg lactose monohydrate.

Rolitac , 1 mg, hard capsules   Each capsule contains 47.4 mg lactose monohydrate.

Rolitac , 5 mg, hard capsules   Each capsule contains 236.9 mg lactose monohydrate.

For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Capsules, hard

Rolitac , 0.5 mg, hard capsules  
Opaque white and ivory hard gelatin capsules containing white to off- white powder.

Rolitac , 1 mg, hard capsules  
Opaque white and light brown hard gelatin capsules containing white to off- white powder.

Rolitac , 5 mg, hard capsules  
Opaque white and orange hard gelatin capsules containing white to off- white powder.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prophylaxis of transplant rejection in liver, kidney or heart allograft recipients.</p><p>&nbsp;</p><p>Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tacrolimus therapy requires careful monitoring by adequately qualified and equipped personnel.</p><p>The medicinal product should only be prescribed, and changes in immunosuppressive therapy&nbsp; initiated, by physicians experienced in immunosuppressive therapy and the management of transplant patients.</p><p>&nbsp;</p><p>Inadvertent, unintentional or unsupervised switching of immediate- or prolonged-release formulations of tacrolimus is unsafe. This can lead to graft rejection or increased incidence of side effects, including under- or overimmunosuppression, due to clinically relevant differences in systemic exposure to tacrolimus. Patients should be maintained on a single formulation of tacrolimus with the&nbsp; corresponding daily dosing regimen; alterations in formulation or regimen should only take place under the close supervision of a transplant specialist (see sections 4.4 and 4.8). Following conversion to any alternative formulation, therapeutic drug monitoring must be performed and dose adjustments made to ensure that systemic exposure to tacrolimus is maintained.</p><p>&nbsp;</p><p>General considerations</p><p>The recommended initial dosages presented below are intended to act solely as a guideline.&nbsp; Tacrolimus dosing should primarily be based on clinical assessments of rejection and tolerability in each patient individually aided by blood level monitoring (see below for recommended target whole blood trough concentrations). If clinical signs of rejection are apparent, alteration of the immunosuppressive regimen should be considered.</p><p>Tacrolimus can be administered intravenously or orally. In general, dosing may commence orally; if necessary, by administering the capsule contents suspended in water, via nasogastric tubing. Tacrolimus is routinely administered in conjunction with other immunosuppressive agents in the&nbsp; initial post-operative period. The tacrolimus dose may vary depending upon the immunosuppressive regimen chosen.</p><p>&nbsp;</p><p>Method of administration</p><p>It is recommended that the oral daily dose be administered in two divided doses (e.g. morning and evening). Capsules should be taken immediately following removal from the blister. The capsules should be swallowed with fluid (preferably water).</p><p>Capsules should generally be administered on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal, to achieve maximal absorption (see section 5.2).</p><p>&nbsp;</p><p>Duration of dosing</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>To suppress graft rejection, immunosuppression must be maintained; consequently, no limit to the duration of oral therapy can be given.</p><p>&nbsp;</p><p>Dosage recommendations &ndash; Liver transplantation</p><p><u>Prophylaxis of transplant rejection - adults</u></p><p>Oral tacrolimus therapy should commence at 0.10-0.20 mg/kg/day administered as two divided doses (e.g. morning and evening). Administration should commence approximately 12 hours after the completion of surgery.</p><p>If the dose cannot be administered orally as a result of the clinical condition of the patient, intravenous therapy of 0.01-0.05 mg/kg/day should be initiated as a continuous 24 hour infusion.</p><p><u>Prophylaxis of transplant rejection - children</u></p><p>An initial oral dose of 0.30 mg/kg/day should be administered in two divided doses (e.g. morning and evening). If the clinical condition of the patient prevents oral dosing, an initial intravenous dose of</p><p>0.05 mg/kg/day should be administered as a continuous 24-hour infusion. <u>Dose adjustment during post-transplant period in adults and children</u></p><p>Tacrolimus doses are usually reduced in the post-transplant period. It is possible in some cases to withdraw concomitant immunosuppressive therapy, leading to tacrolimus monotherapy.</p><p>Post-transplant improvement in the condition of the patient may alter the pharmacokinetics of tacrolimus and may necessitate further dose adjustments.</p><p><u>Rejection therapy &ndash; adults and children</u></p><p>Increased tacrolimus doses, supplemental corticosteroid therapy, and introduction of short courses of mono-/polyclonal antibodies have all been used to manage rejection episodes. If signs of toxicity are noted (e.g. pronounced adverse reactions - see section 4.8) the dose of tacrolimus may need to be reduced.</p><p>For conversion to tacrolimus, treatment should begin with the initial oral dose recommended for primary immunosuppression.</p><p>For information on conversion from ciclosporin to tacrolimus, see below under &ldquo;Dose adjustments in specific patient populations&rdquo;.</p><p>&nbsp;</p><p>Dosage recommendations - Kidney transplantation</p><p><u>Prophylaxis of transplant rejection &ndash; adults</u></p><p>Oral tacrolimus therapy should commence at 0.20-0.30 mg/kg/day administered as two divided doses (e.g. morning and evening). Administration should commence within 24 hours after the completion of surgery.</p><p>If the dose cannot be administered orally as a result of the clinical condition of the patient, intravenous therapy of 0.05-0.10 mg/kg/day should be initiated as a continuous 24 hour infusion.</p><p><u>Prophylaxis of transplant rejection &ndash; children</u></p><p>An initial oral dose of 0.30 mg/kg/day should be administered in two divided doses (e.g. morning and evening). If the clinical condition of the patient prevents oral dosing, an initial intravenous dose of 0.075&ndash;0.100 mg/kg/day should be administered as a continuous 24 hour infusion.</p><p><u>Dose adjustment during post-transplant period in adults and children</u></p><p>Tacrolimus doses are usually reduced in the post-transplant period. It is possible in some cases to withdraw concomitant immunosuppressive therapy, leading to tacrolimus-based dual-therapy.</p><p>Post-transplant improvement in the condition of the patient may alter the pharmacokinetics of tacrolimus and may necessitate further dose adjustments.</p><p><u>Rejection therapy &ndash; adults and children</u></p><p>Increased tacrolimus doses, supplemental corticosteroid therapy, and introduction of short courses of mono-/polyclonal antibodies have all been used to manage rejection episodes. If signs of toxicity are</p><p>&nbsp;</p><p>&nbsp;</p><p>noted (e.g. pronounced adverse reactions - see section 4.8) the dose of tacrolimus may need to be reduced.</p><p>For conversion to tacrolimus, treatment should begin with the initial oral dose recommended for primary immunosuppression.</p><p>For information on conversion from ciclosporin to tacrolimus, see below under &ldquo;Dose adjustments in specific patient populations&rdquo;.</p><p>&nbsp;</p><p>Dosage recommendations - Heart transplantation</p><p><u>Prophylaxis of transplant rejection &ndash; adults</u></p><p>Tacrolimus can be used with antibody induction (allowing for delayed start of tacrolimus therapy) or alternatively in clinically stable patients without antibody induction.</p><p>Following antibody induction, oral Tacrolimus therapy should commence at a dose of 0.075&nbsp; mg/kg/day administered as two divided doses (e.g. morning and evening). Administration should commence within 5 days after the completion of surgery as soon as the patient&#39;s clinical condition is stabilised. If the dose cannot be administered orally as a result of the clinical condition of the patient, intravenous therapy of 0.01 to 0.02 mg/kg/day should be initiated as a continuous 24 hour infusion.</p><p>&nbsp;</p><p>An alternative strategy was published where oral tacrolimus was administered within 12 hours post transplantation. This approach was reserved for patients without organ dysfunction (e.g. renal dysfunction). In that case, an initial oral tacrolimus dose of 2 to 4 mg per day was used in combination with mycophenolate mofetil and corticosteroids or in combination with sirolimus and corticosteroids. <u>Prophylaxis of transplant rejection &ndash; children</u></p><p>Tacrolimus has been used with or without antibody induction in paediatric heart transplantation.</p><p>In patients without antibody induction, if tacrolimus therapy is initiated intravenously, the recommended starting dose is 0.03-0.05 mg/kg/day as a continuous 24-hour infusion targeted to achieve tacrolimus whole blood concentrations of 15-25 ng/ml. Patients should be converted to oral therapy as soon as clinically practicable. The first dose of oral therapy should be 0.30 mg/kg/day starting 8 to 12 hours after discontinuing intravenous therapy.</p><p>Following antibody induction, if tacrolimus therapy is initiated orally, the recommended starting dose is 0.10-0.30 mg/kg/day administered as two divided doses (e.g. morning and evening).</p><p><u>Dose adjustment during post-transplant period in adults and children</u></p><p>Tacrolimus doses are usually reduced in the post-transplant period. Post-transplant improvement in the condition of the patient may alter the pharmacokinetics of tacrolimus and may necessitate further dose adjustments.</p><p><u>Rejection therapy &ndash; adults and children</u></p><p>Increased tacrolimus doses, supplemental corticosteroid therapy, and introduction of short courses of mono-/polyclonal antibodies have all been used to manage rejection episodes.</p><p>In adult patients converted to tacrolimus , an initial oral dose of 0.15 mg/kg/day should be administered in two divided doses (e.g. morning and evening).</p><p>In paediatric patients converted to tacrolimus , an initial oral dose of 0.20-0.30 mg/kg/day should be administered in two divided doses (e.g. morning and evening).</p><p>For information on conversion from ciclosporin to tacrolimus , see below under &ldquo;Dose adjustments in specific patient populations&rdquo;.</p><p>&nbsp;</p><p>Dosage recommendations - Rejection therapy, other allografts</p><p>The dose recommendations for lung, pancreas and intestinal transplantation are based on limited prospective clinical trial data. In lung-transplanted patients tacrolimus has been used at an initial&nbsp; &nbsp;oral</p><p>&nbsp;</p><p>&nbsp;</p><p>dose of 0.10-0.15 mg/kg/day, in pancreas-transplanted patients at an initial oral dose of 0.2 mg/kg/day and in intestinal transplantation at an initial oral dose of 0.3 mg/kg/day.</p><p>&nbsp;</p><p>Dosage adjustments in specific patient populations</p><p><u>Patients with liver impairment</u></p><p>Dose reduction may be necessary in patients with severe liver impairment in order to maintain the blood trough levels within the recommended target range.</p><p><u>Patients with kidney impairment</u></p><p>As the pharmacokinetics of tacrolimus are unaffected by renal function, no dose adjustment should be required. However, owing to the nephrotoxic potential of tacrolimus careful monitoring of renal function is recommended (including serial serum creatinine concentrations, calculation of creatinine clearance and monitoring of urine output).</p><p><u>Paediatric patients</u></p><p>In general, paediatric patients require doses 1&frac12; - 2 times higher than the adult doses to achieve similar blood levels.</p><p><u>Elderly patients</u></p><p>There is no evidence currently available to indicate that dosing should be adjusted in elderly patients. <u>Conversion from ciclosporin</u></p><p>Care should be taken when converting patients from ciclosporin-based to tacrolimus-based therapy&nbsp; (see sections 4.4 and 4.5). Tacrolimus therapy should be initiated after considering ciclosporin blood concentrations and the clinical condition of the patient. Dosing should be delayed in the presence of elevated ciclosporin blood levels. In practice, tacrolimus therapy has been initiated 12-24 hours after discontinuation of ciclosporin. Monitoring of ciclosporin blood levels should be continued following conversion as the clearance of ciclosporin might be affected.</p><p>&nbsp;</p><p>Target whole blood trough concentration recommendations</p><p>Dosing should primarily be based on clinical assessments of rejection and tolerability in each individual patient.</p><p>As an aid to optimise dosing, several immunoassays are available for determining tacrolimus concentrations in whole blood including a semi-automated microparticle enzyme immunoassay (MEIA). Comparisons of concentrations from the published literature to individual values in clinical practice should be assessed with care and knowledge of the assay methods employed. In current clinical practice, whole blood levels are monitored using immunoassay methods.</p><p>Blood trough levels of tacrolimus should be monitored during the post-transplantation period. When dosed orally, blood trough levels should be drawn approximately 12 hours post-dosing, just prior to the next dose. The frequency of blood level monitoring should be based on clinical needs. As tacrolimus is a medicinal product with low clearance, adjustments to the dosage regimen may take several days before changes in blood levels are apparent. Blood trough levels should be monitored approximately twice weekly during the early post-transplant period and then periodically during maintenance therapy. Blood trough levels of tacrolimus should also be monitored following dose adjustment, changes in the immunosuppressive regimen, or following co-administration of substances which may alter tacrolimus whole blood concentrations (see section 4.5).</p><p>Clinical study analysis suggests that the majority of patients can be successfully managed if tacrolimus blood trough levels are maintained below 20 ng/ml. It is necessary to consider the clinical condition of the patient when interpreting whole blood levels.</p><p>In clinical practice, whole blood trough levels have generally been in the range 5-20 ng/ml in liver transplant&nbsp; recipients&nbsp; and&nbsp; 10-20&nbsp; ng/ml&nbsp; in&nbsp; kidney&nbsp; and&nbsp; heart&nbsp; transplant&nbsp; patients&nbsp; in&nbsp; the&nbsp; early&nbsp; post-</p><p>&nbsp;</p><p>&nbsp;</p><p>transplant period. Subsequently, during maintenance therapy, blood concentrations have generally been in the range of 5-15 ng/ml in liver, kidney and heart transplant recipients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to tacrolimus or other macrolides. Hypersensitivity to any of the excipients.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>During the initial post-transplant period, monitoring of the following parameters should be undertaken on a routine basis: blood pressure, ECG, neurological and visual status, fasting blood glucose levels, electrolytes (particularly potassium), liver and renal function tests, haematology parameters, coagulation values, and plasma protein determinations. If clinically relevant changes are seen, adjustments of the immunosuppressive regimen should be considered.</p><p>&nbsp;</p><p>Medication errors, including inadvertent, unintentional or unsupervised substitution of immediate- or prolonged-release tacrolimus formulations, have been observed. This has led to serious adverse events, including graft rejection, or other side effects which could be a consequence of either under- or over- exposure to tacrolimus. Patients should be maintained on a single formulation of tacrolimus with the corresponding daily dosing regimen; alterations in formulation or regimen should only take place under the close supervision of a transplant specialist (see sections 4.2 and 4.8).</p><p>&nbsp;</p><p>Herbal preparations containing St. John&rsquo;s Wort (Hypericum perforatum) or other herbal preparations should be avoided when taking tacrolimus due to the risk of interactions that lead to decrease in blood concentrations of tacrolimus and reduced clinical effect of tacrolimus (see section 4.5).</p><p>Since levels of tacrolimus in blood may significantly change during diarrhoea episodes, extra monitoring of tacrolimus concentrations is recommended during episodes of diarrhoea.</p><p>&nbsp;</p><p>The combined administration of ciclosporin and tacrolimus should be avoided and care should be taken when administering tacrolimus to patients who have previously received ciclosporin (see sections 4.2 and 4.5).</p><p>&nbsp;</p><p>Ventricular hypertrophy or hypertrophy of the septum, reported as cardiomyopathies, have been observed on rare occasions. Most cases have been reversible, occurring primarily in children with tacrolimus blood trough concentrations much higher than the recommended maximum levels. Other factors observed to increase the risk of these clinical conditions included pre-existing heart disease, corticosteroid usage, hypertension, renal or hepatic dysfunction, infections, fluid overload, and oedema. Accordingly, high-risk patients, particularly young children and those receiving substantial immunosuppression should be monitored, using such procedures as echocardiography or ECG pre- and post-transplant (e.g. initially at three months and then at 9-12 months). If abnormalities develop, dose reduction of tacrolimus therapy, or change of treatment to another immunosuppressive agent should be considered. Tacrolimus may prolong the QT interval but at this time lacks substantial evidence for causing Torsades de Pointes. Caution should be exercised in patients with diagnosed or suspected Congenital Long QT Syndrome.</p><p>&nbsp;</p><p>&nbsp;</p><p>Patients treated with tacrolimus have been reported to develop EBV-associated lymphoproliferative disorders. Patients switched to tacrolimus therapy should not receive anti-lymphocyte treatment concomitantly. Very young (&lt; 2 years), EBV-VCA-negative children have been reported to have an increased risk of developing lymphoproliferative disorders. Therefore, in this patient group, EBV- VCA serology should be ascertained before starting treatment with tacrolimus. During treatment, careful monitoring with EBV-PCR is recommended. Positive EBV-PCR may persist for months and is per se not indicative of lymphoproliferative disease or lymphoma.</p><p>&nbsp;</p><p>Patients treated with tacrolimus have been reported to develop posterior reversible encephalopathy syndrome (PRES). If patients taking tacrolimus present with symptoms indicating PRES such as headache, altered mental status, seizures, and visual disturbances, a radiological procedure (e.g. MRI) should be performed. If PRES is diagnosed, adequate blood pressure control and immediate discontinuation of systemic tacrolimus is advised. Most patients completely recover after appropriate measures are taken.</p><p>&nbsp;</p><p>Patients treated with immunosuppressants, including Rolitac , 0.5 mg, hard capsules&nbsp;&nbsp; Rolitac , 1 mg, hard capsules&nbsp;&nbsp; Rolitac , 5 mg, hard capsules&nbsp;&nbsp; are at increased risk of opportunistic infections (bacterial, fungal, viral and protozoal). Among these conditions are BK virus associated nephropathy and JC virus associated progressive multifocal leukoencephalopathy (PML). These infections are often related to a high total immunosuppressive burden and may lead to serious or fatal conditions that physicians should consider in patients with deteriorating renal function or neurological symptoms.</p><p>&nbsp;</p><p>As with other immunosuppressive agents, owing to the potential risk of malignant skin changes, exposure to sunlight and UV light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.</p><p>As with other potent immunosuppressive compounds, the risk of secondary cancer is unknown (see section 4.8).</p><p>&nbsp;</p><p>As Rolitac , 0.5 mg, hard capsules&nbsp;&nbsp; Rolitac , 1 mg, hard capsules&nbsp;&nbsp; Rolitac , 5 mg, hard capsules &nbsp;&nbsp;contains lactose, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Metabolic interactions</u></p><p>Systemically available tacrolimus is metabolised by hepatic CYP3A4. There is also evidence of gastrointestinal metabolism by CYP3A4 in the intestinal wall. Concomitant use of medicinal products or herbal remedies known to inhibit or induce CYP3A4 may affect the metabolism of tacrolimus and thereby increase or decrease tacrolimus blood levels. It is therefore recommended to monitor tacrolimus blood levels whenever substances which have the potential to alter CYP3A metabolism are used concomitantly and to adjust the tacrolimus dose as appropriate in order to maintain similar tacrolimus exposure (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p><u>Inhibitors of metabolism</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Clinically the following substances have been shown to increase tacrolimus blood levels: Strong interactions have been observed with antifungal agents such as ketoconazole, fluconazole, itraconazole and voriconazole, the macrolide antibiotic erythromycin or HIV protease inhibitors (e.g. ritonavir). Concomitant use of these substances may require decreased tacrolimus doses in nearly all patients.</p><p>Weaker interactions have been observed with clotrimazole, clarithromycin, josamycin, nifedipine, nicardipine, diltiazem, verapamil, danazol, ethinylestradiol, omeprazole and nefazodone. <em>In vitro </em>the following substances have been shown to be potential inhibitors of tacrolimus metabolism: bromocriptine, cortisone, dapsone, ergotamine, gestodene, lidocaine, mephenytoin, miconazole, midazolam, nilvadipine, norethindrone, quinidine, tamoxifen, (triacetyl)oleandomycin.</p><p>Grapefruit juice has been reported to increase the blood level of tacrolimus and should therefore be avoided.</p><p>&nbsp;</p><p><u>Inducers of metabolism</u></p><p>Clinically the following substances have been shown to decrease tacrolimus blood levels:</p><p>Strong interactions have been observed with rifampicin, phenytoin or St. John&rsquo;s Wort (Hypericum perforatum) which may require increased tacrolimus doses in almost all patients. Clinically significant interactions have also been observed with phenobarbital. Maintenance doses of corticosteroids have been shown to reduce tacrolimus blood levels.</p><p>High dose prednisolone or methylprednisolone administered for the treatment of acute rejection have the potential to increase or decrease tacrolimus blood levels.</p><p>Carbamazepine, metamizole and isoniazid have the potential to decrease tacrolimus concentrations.</p><p>&nbsp;</p><p><u>Effect of tacrolimus on the metabolism of other medicinal products</u></p><p>Tacrolimus is a known CYP3A4 inhibitor; thus concomitant use of tacrolimus with medicinal products known to be metabolised by CYP3A4 may affect the metabolism of such medicinal products. The half-life of ciclosporin is prolonged when tacrolimus is given concomitantly. In addition, synergistic/additive nephrotoxic effects can occur. For these reasons, the combined administration of ciclosporin and tacrolimus is not recommended and care should be taken when administering tacrolimus to patients who have previously received ciclosporin (see sections 4.2 and 4.4). Tacrolimus has been shown to increase the blood level of phenytoin.</p><p>As tacrolimus may reduce the clearance of steroid-based contraceptives leading to increased hormone exposure, particular care should be exercised when deciding upon contraceptive measures.</p><p>Limited knowledge of interactions between tacrolimus and statins is available. Available data suggests that the pharmacokinetics of statins are largely unaltered by the co-administration of tacrolimus.</p><p>Animal data have shown that tacrolimus could potentially decrease the clearance and increase the half- life of pentobarbital and phenazone.</p><p>&nbsp;</p><p><u>Other interactions which have led to clinically detrimental effects</u></p><p>Concurrent use of tacrolimus with medicinal products known to have nephrotoxic or neurotoxic&nbsp; effects may increase these effects (e.g. aminoglycosides, gyrase inhibitors, vancomycin, cotrimoxazole, NSAIDs, ganciclovir or aciclovir).</p><p>Enhanced nephrotoxicity has been observed following the administration of amphotericin B and ibuprofen in conjunction with tacrolimus.</p><p>As tacrolimus treatment may be associated with hyperkalaemia, or may increase pre-existing hyperkalaemia, high potassium intake, or potassium-sparing diuretics (e.g. amiloride, triamterene or spironolactone) should be avoided.</p><p>Immunosuppressants may affect the response to vaccination and vaccination during treatment with tacrolimus may be less effective. The use of live attenuated vaccines should be avoided.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Protein binding considerations</u></p><p>Tacrolimus is extensively bound to plasma proteins. Possible interactions with other medicinal products known to have high affinity for plasma proteins should be considered (e.g. NSAIDs, oral anticoagulants, or oral anti-diabetics).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Human data show that tacrolimus crosses the placenta. Limited data from organ transplant recipients show no evidence of an increased risk of adverse effects on the course and outcome of pregnancy under tacrolimus treatment compared with other immunosuppressive medicinal products. To date, no other relevant epidemiological data are available. Tacrolimus treatment can be considered in pregnant women when there is no safer alternative and when the perceived benefit justifies the potential risk to the foetus. In case of <em>in utero </em>exposure, monitoring of the newborn for the potential adverse effects of tacrolimus is recommended (in particular the effects on the kidneys). There is a risk for premature delivery (&lt;37 week) as well as for hyperkalaemia in the newborn (incidence 8 of 111 neonates, i.e. 7.2%), which, however, normalizes spontaneously.</p><p>In rats and rabbits, tacrolimus caused embryofoetal toxicity at doses which demonstrated maternal toxicity (see section 5.3). Tacrolimus affected male fertility in rats (see section 5.3).</p><p>&nbsp;</p><p><u>Lactation</u></p><p>Human data demonstrate that tacrolimus is excreted into breast milk. As detrimental effects on the newborn cannot be excluded, women should not breast-feed whilst receiving tacrolimus .</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tacrolimus may cause visual and neurological disturbances. This effect may be enhanced if tacrolimus is administered in association with alcohol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse drug reaction profile associated with immunosuppressive agents is often difficult to establish owing to the underlying disease and the concurrent use of multiple medications.</p><p>&nbsp;</p><p>Many of the adverse drug reactions stated below are reversible and/or respond to dose reduction. Oral administration appears to be associated with a lower incidence of adverse drug reactions compared with intravenous use. Adverse drug reactions are listed below in descending order by frequency of occurrence: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><u>Infections and infestations</u></p><p>As is well known for other potent immunosuppressive agents, patients receiving tacrolimus are frequently at increased risk for infections (viral, bacterial, fungal, protozoal). The course of pre- existing infections may be aggravated. Both generalised and localised infections can occur.</p><p>&nbsp;</p><p>&nbsp;</p><p>Cases of BK virus associated nephropathy, as well as cases of JC virus associated progressive multifocal leukoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including tacrolimus.</p><p>&nbsp;</p><p><u>Neoplasms benign, malignant and unspecified (including cysts and polyps)</u></p><p>Patients receiving immunosuppressive therapy are at increased risk of developing malignancies. Benign as well as malignant neoplasms including EBV-associated lymphoproliferative disorders and skin malignancies have been reported in association with tacrolimus treatment.</p><p>&nbsp;</p><p><u>Blood and lymphatic system disorders</u></p><p>common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaemia,&nbsp; leukopenia,&nbsp; thrombocytopenia,&nbsp; leukocytosis,&nbsp; red&nbsp; blood&nbsp; &nbsp;cell &nbsp;analyses abnormal</p><p>uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; coagulopathies,&nbsp;&nbsp; coagulation&nbsp;&nbsp; and&nbsp;&nbsp; bleeding&nbsp;&nbsp; analyses&nbsp; &nbsp;abnormal,&nbsp; &nbsp;pancytopenia, neutropenia</p><p>rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thrombotic thrombocytopenic purpura, hypo-prothrombinaemia</p><p>&nbsp;</p><p><u>Immune system disorders</u></p><p>Allergic and anaphylactoid reactions have been observed in patients receiving tacrolimus (see section 4.4).</p><p>&nbsp;</p><p><u>Endocrine disorders</u></p><p>rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hirsutism</p><p>&nbsp;</p><p><u>Metabolism and nutrition disorders</u></p><p>very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hyperglycaemic conditions, diabetes mellitus, hyperkalaemia</p><p>common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypomagnesaemia,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypophosphataemia,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;hypokalaemia,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;hypocalcaemia, hyponatraemia, fluid overload, hyperuricaemia, appetite decreased, anorexia, metabolic&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acidoses,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hyperlipidaemia,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypercholesterolaemia, hypertriglyceridaemia, other electrolyte abnormalities</p><p>uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dehydration, hypoproteinaemia, hyperphosphataemia, hypoglycaemia</p><p>&nbsp;</p><p><u>Psychiatric disorders</u></p><p>very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; insomnia</p><p>common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety&nbsp; symptoms,&nbsp; confusion&nbsp; and&nbsp; disorientation,&nbsp; depression,&nbsp; &nbsp;depressed &nbsp;mood, mood disorders and disturbances, nightmare, hallucination, mental disorders</p><p>uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; psychotic disorder</p><p>&nbsp;</p><p><u>Nervous system disorders</u></p><p>very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tremor, headache</p><p>common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizures, disturbances in consciousness, paraesthesias and dysaesthesias, peripheral neuropathies, dizziness, writing impaired, nervous system disorders</p><p>uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; coma,&nbsp;&nbsp; central&nbsp;&nbsp; nervous&nbsp;&nbsp; system&nbsp;&nbsp; haemorrhages&nbsp;&nbsp; and &nbsp;cerebrovascular &nbsp;accidents, paralysis and paresis, encephalopathy, speech and language abnormalities, amnesia</p><p>rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypertonia</p><p>very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; myasthenia</p><p>&nbsp;</p><p><u>Eye disorders</u></p><p>common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vision blurred, photophobia, eye disorders</p><p>&nbsp;</p><p>&nbsp;</p><p>uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cataract</p><p>rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blindness</p><p>&nbsp;</p><p><u>Ear and labyrinth disorders </u>common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tinnitus</p><p>uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypoacusis</p><p>rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; deafness neurosensory</p><p>very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hearing impaired</p><p>&nbsp;</p><p><u>Cardiac disorders</u></p><p>common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ischaemic coronary artery disorders, tachycardia</p><p>uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ventricular&nbsp;&nbsp; arrhythmias&nbsp;&nbsp; and&nbsp;&nbsp; cardiac&nbsp;&nbsp; arrest,&nbsp;&nbsp; heart failures, &nbsp;cardiomyopathies, ventricular hypertrophy, supraventricular arrhythmias, palpitations, ECG investigations abnormal, heart rate and pulse investigations abnormal</p><p>rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pericardial effusion</p><p>very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; echocardiogram abnormal</p><p>&nbsp;</p><p><u>Vascular disorders</u></p><p>very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypertension</p><p>common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; haemorrhage, thrombembolic and ischaemic events, peripheral &nbsp;vascular disorders, vascular hypotensive disorders</p><p>uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infarction, venous thrombosis deep limb, shock</p><p>&nbsp;</p><p><u>Respiratory, thoracic and mediastinal disorders</u></p><p>common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dyspnoea, parenchymal lung disorders, pleural effusion, pharyngitis,&nbsp; &nbsp;cough, nasal congestion and inflammations</p><p>uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; respiratory failures, respiratory tract disorders, asthma rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute respiratory distress syndrome</p><p>&nbsp;</p><p><u>Gastrointestinal disorders</u></p><p>very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea, nausea</p><p>common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gastrointestinal&nbsp;&nbsp;&nbsp;&nbsp; inflammatory&nbsp;&nbsp;&nbsp;&nbsp; conditions,&nbsp;&nbsp;&nbsp;&nbsp; gastrointestinal&nbsp; &nbsp;ulceration&nbsp;&nbsp; &nbsp;and perforation, gastrointestinal haemorrhages, stomatitis and ulceration, ascites, vomiting, gastrointestinal and abdominal pains, dyspeptic signs and symptoms, constipation, flatulence, bloating and distension, loose stools, gastrointestinal signs and symptoms</p><p>uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ileus paralytic, peritonitis, acute and chronic pancreatitis, blood amylase increased, gastrooesophageal reflux disease, impaired gastric emptying</p><p>rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; subileus, pancreatic pseudocyst</p><p>&nbsp;</p><p><u>Hepatobiliary disorders</u></p><p>common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hepatic&nbsp;&nbsp; enzymes&nbsp;&nbsp; and&nbsp;&nbsp; function&nbsp;&nbsp; abnormalities,&nbsp;&nbsp; cholestasis&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; jaundice, hepatocellular damage and hepatitis, cholangitis</p><p>rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hepatitic artery thrombosis, venoocclusive liver disease very rare:&nbsp; hepatic failure, bile duct stenosis</p><p>&nbsp;</p><p><u>Skin and subcutaneous tissue disorders</u></p><p>common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pruritus, rash, alopecias, acne, sweating increased</p><p>&nbsp;</p><p>&nbsp;</p><p>uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dermatitis, photosensitivity</p><p>rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; toxic epidermal necrolysis (Lyell&rsquo;s syndrome)</p><p>very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stevens Johnson syndrome</p><p>&nbsp;</p><p><u>Musculoskeletal and connective tissue disorders</u></p><p>common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; arthralgia, muscle cramps, pain in limb, back pain uncommon:&nbsp;&nbsp; joint disorders</p><p>&nbsp;</p><p><u>Renal and urinary disorders</u></p><p>very common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; renal impairment</p><p>common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; renal failure, renal failure acute, oliguria, renal tubular necrosis, nephropathy toxic, urinary abnormalities, bladder and urethral symptoms</p><p>uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anuria, haemolytic uraemic syndrome very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nephropathy, cystitis haemorrhagic</p><p>&nbsp;</p><p><u>Reproductive system and breast disorders</u></p><p>uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dysmenorrhoea and uterine bleeding</p><p>&nbsp;</p><p><u>General disorders and administration site conditions</u></p><p>common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; asthenic conditions, febrile disorders, oedema, pain and discomfort, &nbsp;blood alkaline phosphatase increased, weight increased, body temperature perception disturbed</p><p>uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; multi-organ failure, influenza like illness, temperature intolerance,&nbsp;&nbsp; &nbsp;chest pressure sensation, feeling jittery, feeling abnormal, blood lactate dehydrogenase increased, weight decreased</p><p>rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thirst, fall, chest tightness, mobility decreased, ulcer</p><p>very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fat tissue increased</p><p>&nbsp;</p><p><u>Injury, poisoning and procedural complications </u>common:&nbsp;&nbsp; primary graft dysfunction</p><p>&nbsp;</p><p>Medication errors, including inadvertent, unintentional or unsupervised substitution of immediate- or prolonged-release tacrolimus formulations, have been observed. A number of associated cases of transplant rejection have been reported (frequency cannot be estimated from available data).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Experience with over dosage is limited. Several cases of accidental over dosage have been reported; symptoms have included tremor, headache, nausea and vomiting, infections, urticaria, lethargy, increased blood urea nitrogen and elevated serum creatinine concentrations, and increase in alanine aminotransferase levels.</p><p>No specific antidote to tacrolimus therapy is available. If over dosage occurs, general supportive measures and symptomatic treatment should be conducted. Based on its high molecular weight, poor aqueous solubility, and extensive erythrocyte and plasma protein binding, it is anticipated that tacrolimus will not be dialysable. In isolated patients with very high plasma levels, haemofiltration &nbsp;or</p><p>-diafiltration have been effective in reducing toxic concentrations. In cases of oral intoxication, gastric lavage and/or the use of adsorbents (such as activated charcoal) may be helpful, if used shortly after intake.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Calcineurin inhibitors, ATC code: L04AD02 <u>Mechanism of action and pharmacodynamic effects</u></p><p>At the molecular level, the effects of tacrolimus appear to be mediated by binding to a cytosolic&nbsp; protein (FKBP12) which is responsible for the intracellular accumulation of the compound. The FKBP12-tacrolimus complex specifically and competitively binds to and inhibits calcineurin, leading to a calcium-dependent inhibition of T-cell signal transduction pathways, thereby preventing transcription of a discrete set of lymphokine genes.</p><p>Tacrolimus is a highly potent immunosuppressive agent and has proven activity in both <em>in vitro </em>and <em>in vivo </em>experiments.</p><p>&nbsp;</p><p>In particular, tacrolimus inhibits the formation of cytotoxic lymphocytes, which are mainly&nbsp; responsible for graft rejection. Tacrolimus suppresses T-cell activation and T-helper-cell dependent B- cell proliferation, as well as the formation of lymphokines (such as interleukins-2, -3, and &gamma;-interferon) and the expression of the interleukin-2 receptor.</p><p>&nbsp;</p><p><u>Results from published data in other primary organ transplantation</u></p><p>Tacrolimus has evolved into an accepted treatment as primary immunosuppressive medicinal product following pancreas, lung and intestinal transplantation. In prospective published studies tacrolimus&nbsp; was investigated as primary immunosuppressant in approximately 175 patients following lung, 475 patients following pancreas and 630 patients following intestinal transplantation. Overall, the safety profile of tacrolimus in these published studies appeared to be similar to what was reported in the large studies, where tacrolimus was used as primary treatment in liver, kidney and heart transplantation. Efficacy results of the largest studies in each indication are summarised below.</p><p><u>Lung transplantation</u></p><p>The interim analysis of a recent multi-centre study discussed 110 patients who underwent 1:1 randomisation to either tacrolimus or ciclosporin. Tacrolimus was started as continuous intravenous infusion at a dose of 0.01 to 0.03 mg/kg/day and oral tacrolimus was administered at a dose of 0.05&nbsp; to</p><p>0.3 mg/kg/day. A lower incidence of acute rejection episodes for tacrolimus- versus ciclosporintreated patients (11.5% versus 22.6%) and a lower incidence of chronic rejection, the bronchiolitis obliterans syndrome (2.86% versus 8.57%), was reported within the first year after transplantation. The 1-year patient survival rate was 80.8% in the tacrolimus and 83% in the ciclosporin group (Treede et al., 3rd ICI San Diego, US, 2004;Abstract 22).</p><p>Another randomised study included 66 patients on tacrolimus versus 67 patients on ciclosporin. Tacrolimus was started as continuous intravenous infusion at a dose of 0.025 mg/kg/day and oral tacrolimus was administered at a dose of 0.15 mg/kg/day with subsequent dose adjustments to target trough levels of 10 to 20 ng/ml. The 1-year patient survival was 83% in the tacrolimus and 71% in the ciclosporin group, the 2 year survival rates were 76% and 66%, respectively. Acute rejection episodes per 100 patient-days were numerically fewer in the tacrolimus (0.85 episodes) than in the ciclosporin group (1.09 episodes). Obliterative bronchiolitis developed in 21.7% of patients in the tacrolimus group compared with 38.0% of patients in the ciclosporin group (p = 0.025). Significantly more ciclosporin-treated patients (n = 13) required a switch to tacrolimus than tacrolimus-treated patients to ciclosporin (n = 2) (p = 0.02) (Keenan et al., Ann Thoracic Surg 1995;60:580).</p><p>&nbsp;</p><p>&nbsp;</p><p>In an additional two-centre study, 26 patients were randomised to the tacrolimus versus 24 patients to the ciclosporin group. Tacrolimus was started as continuous intravenous infusion at a dose of 0.05 mg/kg/day and oral tacrolimus was administered at a dose of 0.1 to 0.3 mg/kg/day with subsequent dose adjustments to target trough levels of 12 to 15 ng/ml. The 1-year survival rates were 73.1% in the tacrolimus versus 79.2% in the ciclosporin group. Freedom from acute rejection was higher in the tacrolimus group at 6 months (57.7% versus 45.8%) and at 1 year after lung transplantation (50% versus 33.3%) (Treede et al., J Heart Lung Transplant 2001;20:511).</p><p>The three studies demonstrated similar survival rates. The incidences of acute rejection were numerically lower with tacrolimus in all three studies and one of the studies reported a significantly lower incidence of bronchiolitis obliterans syndrome with tacrolimus.</p><p><u>Pancreas transplantation</u></p><p>A multi-centre study included 205 patients undergoing simultaneous pancreas-kidney transplantation who were randomised to tacrolimus (n = 103) or to ciclosporin (n = 102). The initial oral per protocol dose of tacrolimus was 0.2 mg/kg/day with subsequent dose adjustments to target trough levels of 8 to 15 ng/ml by Day 5 and 5 to 10 ng/mL after Month 6. Pancreas survival at 1 year was significantly superior with tacrolimus: 91.3% versus 74.5% with ciclosporin (p &lt; 0.0005), whereas renal graft survival was similar in both groups. In total 34 patients switched treatment from ciclosporin to tacrolimus, whereas only 6 tacrolimus patients required alternative therapy (Bechstein et al., Transplantation 2004;77:1221).</p><p><u>Intestinal transplantation</u></p><p>Published clinical experience from a single centre on the use of tacrolimus for primary treatment following intestinal transplantation showed that the actuarial survival rate of 155 patients (65 intestine alone, 75 liver and intestine, and 25 multi-visceral) receiving tacrolimus and prednisone was 75% at 1 year, 54% at 5 years, and 42% at 10 years. In the early years the initial oral dose of tacrolimus was 0.3 mg/kg/day. Results continuously improved with increasing experience over the course of 11 years.</p><p>A variety of innovations, such as techniques for early detection of Epstein-Barr (EBV) and CMV infections, bone marrow augmentation, the adjunct use of the interleukin-2 antagonist daclizumab, lower initial tacrolimus doses with target trough levels of 10 to 15 ng/ml, and most recently allograft irradiation were considered to have contributed to improved results in this indication over time (Abu- Elmagd et al., Ann Surg 2001;234:404).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>In man tacrolimus has been shown to be able to be absorbed throughout the gastrointestinal tract. Following oral administration of tacrolimus capsules peak concentrations (Cmax) of tacrolimus in blood are achieved in approximately 1-3 hours. In some patients, tacrolimus appears to be continuously absorbed over a prolonged period yielding a relatively flat absorption profile. The mean oral bioavailability of tarolimus is in the range of 20-25%.</p><p>After oral administration (0.30 mg/kg/day) to liver transplant patients, steady-state concentrations of tacrolimus were achieved within 3 days in the majority of patients.</p><p>In healthy subjects, Tacrolimus 0.5 mg, Tacrolimus 1 mg and Tacrolimus 5 mg Capsules, hard, have been shown to be bioequivalent, when administered as equivalent dose.</p><p>The rate and extent of absorption of tacrolimus is greatest under fasted conditions. The presence of food decreases both the rate and extent of absorption of tacrolimus, the effect being most pronounced after a high-fat meal. The effect of a high-carbohydrate meal is less pronounced.</p><p>&nbsp;</p><p>&nbsp;</p><p>In stable liver transplant patients, the oral bioavailability of tacrolimus was reduced when it was administered after a meal of moderate fat (34% of calories) content. Decreases in AUC (27%) and&nbsp; Cmax (50%), and an increase in tmax (173%) in whole blood were evident.</p><p>In a study of stable renal transplant patients who were administered tacrolimus immediately after a standard continental breakfast the effect on oral bioavailability was less pronounced. Decreases in AUC (2 to 12%) and Cmax (15 to 38%), and an increase in tmax (38 to 80%) in whole blood were evident.</p><p>Bile flow does not influence the absorption of tacrolimus.</p><p>A strong correlation exists between AUC and whole blood trough levels at steady-state. Monitoring of whole blood trough levels therefore provides a good estimate of systemic exposure.</p><p>&nbsp;</p><p><u>Distribution and elimination</u></p><p>In man, the disposition of tacrolimus after intravenous infusion may be described as biphasic.</p><p>In the systemic circulation, tacrolimus binds strongly to erythrocytes resulting in an approximate 20:1 distribution ratio of whole blood/plasma concentrations. In plasma, tacrolimus is highly bound (&gt; 98.8%) to plasma proteins, mainly to serum albumin and &alpha;-1-acid glycoprotein.</p><p>Tacrolimus is extensively distributed in the body. The steady-state volume of distribution based on plasma concentrations is approximately 1300 l (healthy subjects). Corresponding data based on whole blood averaged 47.6 l.</p><p>Tacrolimus is a low-clearance substance. In healthy subjects, the average total body clearance (TBC) estimated from whole blood concentrations was 2.25 l/h. In adult liver, kidney and heart transplant patients, values of 4.1 l/h, 6.7 l/h and 3.9 l/h, respectively, have been observed. Paediatric liver transplant recipients have a TBC approximately twice that of adult liver transplant patients. Factors such as low haematocrit and protein levels, which result in an increase in the unbound fraction of tacrolimus, or corticosteroid-induced increased metabolism are considered to be responsible for the higher clearance rates observed following transplantation.</p><p>The half-life of tacrolimus is long and variable. In healthy subjects, the mean half-life in whole blood is approximately 43 hours. In adult and paediatric liver transplant patients, it averaged 11.7 hours&nbsp; and</p><p>12.4 hours, respectively, compared with 15.6 hours in adult kidney transplant recipients. Increased clearance rates contribute to the shorter half-life observed in transplant recipients.</p><p>&nbsp;</p><p><u>Metabolism and biotransformation</u></p><p>Tacrolimus is widely metabolised in the liver, primarily by the cytochrome P450-3A4. Tacrolimus is also considerably metabolised in the intestinal wall. There are several metabolites identified. Only one of these has been shown <em>in vitro </em>to have immunosuppressive activity similar to that of tacrolimus. The other metabolites have only weak or no immunosuppressive activity. In systemic circulation only one of the inactive metabolites is present at low concentrations. Therefore, metabolites do not contribute to pharmacological activity of tacrolimus.</p><p>&nbsp;</p><p><u>Excretion</u></p><p>Following intravenous and oral administration of 14C-labelled tacrolimus, most of the radioactivity</p><p>was eliminated in the faeces. Approximately 2% of the radioactivity was eliminated in the urine. Less than 1% of unchanged tacrolimus was detected in the urine and faeces, indicating that tacrolimus is almost completely metabolised prior to elimination: bile being the principal route of elimination.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The kidneys and the pancreas were the primary organs affected in toxicity studies performed in rats and baboons. In rats, tacrolimus caused toxic effects to the nervous system and the eyes. Reversible cardiotoxic effects were observed in rabbits following intravenous administration of tacrolimus. Embryofoetal toxicity was observed in rats and rabbits and was limited to doses that caused significant toxicity in maternal animals. In rats, female reproductive function including birth was impaired at&nbsp; toxic dosages and the offspring showed reduced birth weights, viability and growth.</p><p>A negative effect of tacrolimus on male fertility in the form of reduced sperm counts and motility was observed in rats.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Capsule contents</em></p><p>Hypromellose (Methocel E6 LV) Lactose monohydrate Croscarmellose Sodium Magnesium stearate</p><p>&nbsp;</p><p><em>Hard gelatine capsule:</em></p><p>Rolitac , 0.5 mg&nbsp;</p><p>Gelatin</p><p>Titanium dioxide (E 171) Sodium laurilsulfate Sorbitan laureate</p><p>Yellow iron oxide (E 172)</p><p>&nbsp;</p><p>Rolitac , 1 mg&nbsp;</p><p>Gelatin</p><p>Titanium dioxide (E 171) Sodium laurilsulfate Sorbitan laureate</p><p>Yellow iron oxide (E 172) Red iron oxide (E 172) Black iron oxide (E 172)</p><p>&nbsp;</p><p>Rolitac , 5 mg&nbsp;</p><p>Gelatin</p><p>Titanium dioxide (E 171) Sodium laurilsulfate Sorbitan laureate</p><p>Red iron oxide (E 172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tacrolimus is not compatible with PVC. Tubing, syringes and other equipment used to prepare or administer a suspension of Tacrolimus capsule contents should not contain PVC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years

After opening the bag: 3 months. Do not store above 25°C.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special temperature storage conditions. Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/ PE/ PVdC/ Aluminium blisters with dessicant in Aluminium bag.</p><p>&nbsp;</p><p>Rolitac , 0.5 mg, hard capsules&nbsp;&nbsp; Rolitac , 1 mg, hard capsules&nbsp;&nbsp; Rolitac , 5 mg, hard capsules&nbsp;&nbsp; Packs of Rolitac hard capsules</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Sandoz GmbH
	Biochemiestrasse 10 Kundl, Austria

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                june 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>